StemCell Institute (TSE:7096) Beneish M-Score: -2.11 (As of Jul. 13, 2026)

What is StemCell Institute Beneish M-Score?

StemCell Institute TSE:7096 +0.92% 69 Beneish M-Score is -2.11 as of Jul. 13, 2026. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.29 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 825 Biotechnology companies, StemCell Institute ranks worse than 58.55% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.11 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for StemCell Institute's Beneish M-Score or its related term are showing as below:

TSE:7096' s Beneish M-Score Range Over the Past 10 Years
Min: -2.46 Med: -1.9 Max: -1.51
Current: -2.11

During the past 9 years, the highest Beneish M-Score of StemCell Institute was -1.51. The lowest was -2.46. And the median was -1.90.

StemCell Institute Beneish M-Score Related Terms

StemCell Institute Beneish M-Score Historical Data

* Premium members only.

The historical data trend for StemCell Institute's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute Beneish M-Score Chart

StemCell Institute Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Beneish M-Score

Get a 7-Day Free Trial

-1.81

-1.51

-1.78

-2.46

-2.11

StemCell Institute Semi-Annual Data
	Mar18	Mar19	Mar20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
Beneish M-Score	Get a 7-Day Free Trial									-1.78	0.00	-2.46	0.00	-2.11

TSE:7096 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, StemCell Institute's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StemCell Institute Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCell Institute's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where StemCell Institute's Beneish M-Score falls into.

Save Embed

69GF Score

StemCell Institute TSE:7096

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

StemCell Institute Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of StemCell Institute for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.21

0.528 * 1.037

0.404 * 1.1304

0.892 * 1.0493

0.115 * 0.9764

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1

4.679 * 0.010143

0.327 * 0.9552

-2.11

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was 円2,337 Mil.
Revenue was 円2,811 Mil.
Gross Profit was 円1,712 Mil.
Total Current Assets was 円5,314 Mil.
Total Assets was 円8,125 Mil.
Property, Plant and Equipment(Net PPE) was 円1,375 Mil.
Depreciation, Depletion and Amortization(DDA) was 円157 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円4,532 Mil.
Long-Term Debt & Capital Lease Obligation was 円403 Mil.
Net Income was 円156 Mil.
Gross Profit was 円0 Mil.
Cash Flow from Operations was 円74 Mil.

Total Receivables was 円1,841 Mil.
Revenue was 円2,679 Mil.
Gross Profit was 円1,692 Mil.
Total Current Assets was 円5,172 Mil.
Total Assets was 円7,501 Mil.
Property, Plant and Equipment(Net PPE) was 円1,156 Mil.
Depreciation, Depletion and Amortization(DDA) was 円128 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円4,318 Mil.
Long-Term Debt & Capital Lease Obligation was 円452 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(2337.026 / 2811.344)	/	(1840.677 / 2679.175)
	=	0.831284	/	0.687031
	=	1.21

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(1692.09 / 2679.175)	/	(1712.187 / 2811.344)
	=	0.631571	/	0.609028
	=	1.037

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (5313.624 + 1375.042) / 8124.841)	/	(1 - (5172.467 + 1155.563) / 7500.939)
	=	0.176763	/	0.156368
	=	1.1304

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	2811.344	/	2679.175
	=	1.0493

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(128.278 / (128.278 + 1155.563))	/	(156.757 / (156.757 + 1375.042))
	=	0.099917	/	0.102335
	=	0.9764

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(0 / 2811.344)	/	(0 / 2679.175)
	=	0	/	0
	=	1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((402.937 + 4532.174) / 8124.841)	/	((451.735 + 4318.05) / 7500.939)
	=	0.60741	/	0.635892
	=	0.9552

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(155.917 - 0	-	73.509)	/	8124.841
	=	0.010143

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

StemCell Institute has a M-score of -2.11 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.11 mean?

StemCell Institute (TSE:7096) has a Beneish M-Score of -2.11 as of Jul. 13, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on StemCell Institute and its competitors. According to the industry distribution chart, StemCell Institute ranks #483 out of 825 companies in the Biotechnology industry, placing it in the top 58.5%.

Is StemCell Institute's Beneish M-Score too high?

StemCell Institute's current Beneish M-Score is -2.11. Based on the distribution chart, StemCell Institute ranks #483 out of 825 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does StemCell Institute's Beneish M-Score compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, StemCell Institute ranks #483 out of 825 companies for Beneish M-Score. This places StemCell Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on StemCell Institute and its competitors. StemCell Institute's current Beneish M-Score is -2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is StemCell Institute stock overvalued right now?

Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.29, compared to a current price of 円768.00 — trading 57.6% below its estimated fair value. The current Beneish M-Score is -2.11. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Beneish M-Score is -2.11 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円768.00 is trading 57.6% below its estimated GF Value™ of 円1,813.29. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

Beneish M-Score: -2.11
GF Value™: 円1,813.29 vs. price of 円768.00 (57.6% below fair value)
GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

StemCell Institute Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:3750 TSE:4584 TSE:2370 TSE:4564 TSE:2385 TSE:7776 TSE:4596 TSE:4571 TSE:4594 TSE:4880 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001

Website https://www.stemcell.co.jp

StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.

69GF Score

Get the complete analysis for TSE:7096

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円768.00

Price

円1,813.29

GF Value

View TSE:7096 Analysis

See Beneish M-Score data for all stocks →